Literature DB >> 3876389

Antigen presentation by Hodgkin's disease cells.

R I Fisher, J Cossman, V Diehl, D J Volkman.   

Abstract

The L428 tumor cell line is a long-term tissue culture of Reed-Sternberg cells which was derived from the pleural effusion of a patient with Hodgkin's disease. The L428 cells express all known cell surface antigens, cytochemical staining, and cytologic features of freshly explanted Reed-Sternberg cells. In addition to the previously described HLA-DR cell surface antigens, the L428 cells are now demonstrated to express both DS and SB alloantigens. Thus, the L428 cells express all of the known subclasses of the human immune response genes that are located in the major histocompatibility complex. Furthermore, the L428 cells are capable of presenting soluble antigen to T cells in a genetically restricted fashion. T cell lines were established from normal donors previously immunized with tetanus toxoid. The T cells utilized were incapable of tetanus toxoid-induced proliferation unless antigen-presenting cells were added to the cultures. However, T cells from the two normal donors, which like the L428 cells expressed HLA-DR 5, demonstrated significant proliferative responses when cultured with tetanus toxoid and L428 cells. No proliferative response was observed when the L428 cells were used as antigen-presenting cells for a DR (4,-), DR (2,-) or DR (1,7) T cell line. The tetanus toxoid dose-response curve was similar regardless of whether autologous mononuclear leukocytes or L428 cells were used as antigen-presenting cells. The T cell proliferation induced by soluble antigen was also blocked by anti-HLA-DR antibody. Thus, functionally, Hodgkin's disease may be classified as a tumor of antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876389

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Hodgkin's cells express a novel pattern of adhesion molecules.

Authors:  P A Ellis; D N Hart; B M Colls; J C Nimmo; J E MacDonald; H B Angus
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

2.  Nodular sclerosing, mixed cellularity and lymphocyte-depleted variants of Hodgkin's disease are probable dendritic cell malignancies.

Authors:  I C Kennedy; D N Hart; B M Colls; J C Nimmo; D A Willis; H B Angus
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

Review 3.  Hodgkin's disease: the Sternberg-Reed cell.

Authors:  P Bucsky
Journal:  Blut       Date:  1987-11

4.  Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells.

Authors:  Benjamin Rengstl; Frederike Schmid; Christian Weiser; Claudia Döring; Tim Heinrich; Kathrin Warner; Petra S A Becker; Robin Wistinghausen; Sima Kameh-Var; Eva Werling; Arne Billmeier; Christian Seidl; Sylvia Hartmann; Hinrich Abken; Ralf Küppers; Martin-Leo Hansmann; Sebastian Newrzela
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

5.  Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein-Barr virus infection.

Authors:  P G Murray; J Oates; G M Reynolds; J Crocker; L S Young
Journal:  Clin Mol Pathol       Date:  1995-04

6.  Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.

Authors:  L P Ruco; D Pomponi; R Pigott; A Stoppacciaro; F Monardo; S Uccini; D Boraschi; A Tagliabue; A Santoni; E Dejana
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

7.  Hodgkin's disease cell lines: a model for interleukin-1-independent accessory cell function.

Authors:  J L McKenzie; W Egner; V L Calder; D N Hart
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.